Real-World Dose Trajectory Patterns and Impact on Polypharmacy Burden and New Antiseizure Medication (ASM) Prescriptions in Patients With Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS), or Tuberous Sclerosis Complex (TSC) Receiving Cannabidiol (CBD)

Real-world dose trajectory patterns for CBD in epilepsy patients had not been characterized, limiting understanding of how CBD is optimized in clinical practice.

Target RWE researchers analyzed longitudinal CBD dose trajectory data in real-world epilepsy patients, characterizing dose titration patterns, time to stable dosing, and the relationship between dose trajectory and ASM polypharmacy burden.

Characterizing CBD dose trajectory patterns provides Jazz Pharmaceuticals with real-world prescribing behavior evidence for label optimization and clinical guideline development.

CBD dose trajectory characterization for epilepsy prescribing behavior and label optimization for Jazz Pharmaceuticals, Real-world dose titration evidence for cannabidiol clinical guideline development in treatment-resistant epilepsy